S&P 500   4,293.93
DOW   33,833.61
QQQ   353.15
High Dividend REITs: Are They an Ideal Way to Diversify?
This Company Is Solving A Multi-Billion Dollar Problem! (Ad)
Stock market today: Asian shares mostly rise, lifted by bull market on Wall Street
2 Dow Stocks Trading Less Than 10x Earnings are Blue Chip Values
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Boost for homebuyers: Average long-term US mortgage rate eases from 7-month high to 6.71% this week
6 Best Online and Direct Marketing Retail Stocks to Invest in
This Company Is Solving A Multi-Billion Dollar Problem! (Ad)
Homebuilding Stocks Defying Cooling Housing Market: Time to Sell?
US applications for jobless benefits highest since October 2021
S&P 500   4,293.93
DOW   33,833.61
QQQ   353.15
High Dividend REITs: Are They an Ideal Way to Diversify?
This Company Is Solving A Multi-Billion Dollar Problem! (Ad)
Stock market today: Asian shares mostly rise, lifted by bull market on Wall Street
2 Dow Stocks Trading Less Than 10x Earnings are Blue Chip Values
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Boost for homebuyers: Average long-term US mortgage rate eases from 7-month high to 6.71% this week
6 Best Online and Direct Marketing Retail Stocks to Invest in
This Company Is Solving A Multi-Billion Dollar Problem! (Ad)
Homebuilding Stocks Defying Cooling Housing Market: Time to Sell?
US applications for jobless benefits highest since October 2021
S&P 500   4,293.93
DOW   33,833.61
QQQ   353.15
High Dividend REITs: Are They an Ideal Way to Diversify?
This Company Is Solving A Multi-Billion Dollar Problem! (Ad)
Stock market today: Asian shares mostly rise, lifted by bull market on Wall Street
2 Dow Stocks Trading Less Than 10x Earnings are Blue Chip Values
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Boost for homebuyers: Average long-term US mortgage rate eases from 7-month high to 6.71% this week
6 Best Online and Direct Marketing Retail Stocks to Invest in
This Company Is Solving A Multi-Billion Dollar Problem! (Ad)
Homebuilding Stocks Defying Cooling Housing Market: Time to Sell?
US applications for jobless benefits highest since October 2021
S&P 500   4,293.93
DOW   33,833.61
QQQ   353.15
High Dividend REITs: Are They an Ideal Way to Diversify?
This Company Is Solving A Multi-Billion Dollar Problem! (Ad)
Stock market today: Asian shares mostly rise, lifted by bull market on Wall Street
2 Dow Stocks Trading Less Than 10x Earnings are Blue Chip Values
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Boost for homebuyers: Average long-term US mortgage rate eases from 7-month high to 6.71% this week
6 Best Online and Direct Marketing Retail Stocks to Invest in
This Company Is Solving A Multi-Billion Dollar Problem! (Ad)
Homebuilding Stocks Defying Cooling Housing Market: Time to Sell?
US applications for jobless benefits highest since October 2021
NASDAQ:MCRB

Seres Therapeutics (MCRB) Stock Forecast, Price & News

$5.60
+0.24 (+4.48%)
(As of 06/8/2023 ET)
Compare
Today's Range
$5.12
$5.60
50-Day Range
$4.67
$6.55
52-Week Range
$2.50
$9.49
Volume
2.78 million shs
Average Volume
2.11 million shs
Market Capitalization
$716.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.00

Seres Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
150.0% Upside
$14.00 Price Target
Short Interest
Bearish
11.74% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.14
Upright™ Environmental Score
News Sentiment
0.16mentions of Seres Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$36,527 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.89) to ($1.48) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.95 out of 5 stars

Medical Sector

553rd out of 986 stocks

Pharmaceutical Preparations Industry

257th out of 471 stocks


MCRB stock logo

About Seres Therapeutics (NASDAQ:MCRB) Stock

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Receive MCRB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seres Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MCRB Stock News Headlines

Stop Trading Like A Turtle
Performing at your best requires quick reaction and adaptability. While slow and steady progress works for some, having a tool that enables informed trading decisions is essential amid volatility. It's 2023. Why trade like a turtle when you could track down new opportunities like a cheetah?
Seres Therapeutics (NASDAQ:MCRB) Shares Down 5.9%
Stop Trading Like A Turtle
Performing at your best requires quick reaction and adaptability. While slow and steady progress works for some, having a tool that enables informed trading decisions is essential amid volatility. It's 2023. Why trade like a turtle when you could track down new opportunities like a cheetah?
Seres Therapeutics (NASDAQ: MCRB)
Seres Q1 Earnings: Major News For Investors
See More Headlines

MCRB Price History

MCRB Company Calendar

Last Earnings
5/09/2023
Today
6/08/2023
Next Earnings (Estimated)
8/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MCRB
Fax
N/A
Employees
333
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$14.00
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+150.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
5 Analysts

Profitability

Net Income
$-250,160,000.00
Net Margins
-3,509.50%
Pretax Margin
-5,177.14%

Debt

Sales & Book Value

Annual Sales
$7.13 million
Book Value
$0.09 per share

Miscellaneous

Free Float
121,762,000
Market Cap
$716.24 million
Optionable
Optionable
Beta
2.65

Key Executives

  • Eric D. Shaff
    President, Chief Executive Officer & Director
  • Marcus Chapman
    Senior Vice President-Operations
  • David A. Arkowitz
    CFO, Executive VP & Head-Business Development
  • Matthew R. Henn
    Chief Scientific Officer & Executive VP
  • Barbara McGovern
    Vice President-Medical Affairs













MCRB Stock - Frequently Asked Questions

Should I buy or sell Seres Therapeutics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seres Therapeutics in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MCRB shares.
View MCRB analyst ratings
or view top-rated stocks.

What is Seres Therapeutics' stock price forecast for 2023?

5 brokerages have issued 12-month price targets for Seres Therapeutics' stock. Their MCRB share price forecasts range from $7.00 to $25.00. On average, they predict the company's share price to reach $14.00 in the next year. This suggests a possible upside of 150.0% from the stock's current price.
View analysts price targets for MCRB
or view top-rated stocks among Wall Street analysts.

How have MCRB shares performed in 2023?

Seres Therapeutics' stock was trading at $5.60 at the beginning of the year. Since then, MCRB stock has increased by 0.0% and is now trading at $5.60.
View the best growth stocks for 2023 here
.

Are investors shorting Seres Therapeutics?

Seres Therapeutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 15,010,000 shares, an increase of 23.2% from the April 30th total of 12,180,000 shares. Based on an average trading volume of 2,770,000 shares, the short-interest ratio is currently 5.4 days.
View Seres Therapeutics' Short Interest
.

When is Seres Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our MCRB earnings forecast
.

How were Seres Therapeutics' earnings last quarter?

Seres Therapeutics, Inc. (NASDAQ:MCRB) issued its earnings results on Tuesday, May, 9th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.57). The biotechnology company had revenue of ($0.52) million for the quarter, compared to analyst estimates of $1.58 million. Seres Therapeutics had a negative trailing twelve-month return on equity of 1,977.08% and a negative net margin of 3,509.50%. The business's revenue for the quarter was down 134.8% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.61) earnings per share.

What other stocks do shareholders of Seres Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seres Therapeutics investors own include OPKO Health (OPK), TherapeuticsMD (TXMD), Juno Therapeutics (JUNO), NVIDIA (NVDA), Walt Disney (DIS), Alibaba Group (BABA), Novavax (NVAX), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX) and Gilead Sciences (GILD).

When did Seres Therapeutics IPO?

(MCRB) raised $101 million in an initial public offering (IPO) on Friday, June 26th 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.

What is Seres Therapeutics' stock symbol?

Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB."

Who are Seres Therapeutics' major shareholders?

Seres Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include FMR LLC (14.79%), Federated Hermes Inc. (11.95%), BlackRock Inc. (4.89%), State Street Corp (2.95%), Geode Capital Management LLC (1.28%) and Avoro Capital Advisors LLC (1.01%). Insiders that own company stock include David S Ege and Health Ltp Fund Ge Nutritional.
View institutional ownership trends
.

How do I buy shares of Seres Therapeutics?

Shares of MCRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Seres Therapeutics' stock price today?

One share of MCRB stock can currently be purchased for approximately $5.60.

How much money does Seres Therapeutics make?

Seres Therapeutics (NASDAQ:MCRB) has a market capitalization of $716.24 million and generates $7.13 million in revenue each year. The biotechnology company earns $-250,160,000.00 in net income (profit) each year or ($2.30) on an earnings per share basis.

How many employees does Seres Therapeutics have?

The company employs 333 workers across the globe.

How can I contact Seres Therapeutics?

Seres Therapeutics' mailing address is 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139. The official website for the company is www.serestherapeutics.com. The biotechnology company can be reached via phone at (617) 945-9626 or via email at ctanzi@serestherapeutics.com.

This page (NASDAQ:MCRB) was last updated on 6/9/2023 by MarketBeat.com Staff

My Account -